Moderators: Bhavana Pothuri, MD and Matthew Powell, MD 

Presentations:

• (LBA) Overall survival among patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial (Matthew A. Powell, MD)
• (LBA) Overall Survival and Progression Free Survival by PD-L1 status in Endometrial Cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial (Ramez N. Eskander, MD)
• (LBA) Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy in patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial ( Mansoor R. Mirza, MD)
• Distillation: Endometrial Cancer: Integrating Frontline Immunotherapy into Practice (Gini Fleming, MD)
• (LBA) Raludotatug deruxtecan (R-DXd) monotherapy in patients with previously treated ovarian cancer (OVC): subgroup analysis of a first-in-human phase 1 study (Kathleen Moore, MD)
• Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: biomarker and subgroup analyses from the cervical, endometrial, and ovarian cancer cohorts of the DESTINY-PanTumor02 study (Vikky Maker, MD)
• Distillation: Carol Aghajanian, MD 
• Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study (Linda Duska, MD)
• Patient-Reported Outcomes from the Phase 3, Randomized, Double-Blind, Placebo-Controlled ENGOT-cx11/GOG 3047/KEYNOTE-A18 Study of Pembrolizumab Plus Concurrent Chemoradiotherapy (CCRT) among Patients With High-Risk Locally Advanced Cervical Cancer (LACC) (Leslie M. Randall, MD)
• (Encore Plus) Efficacy and Safety of Tisotumab Vedotin Versus Investigator’s Choice of Chemotherapy in 2L or 3L Recurrent or Metastatic Cervical Cancer (innovaTV 301/ENGOT-cx12/GOG-3057): A Global, Randomized, Open-Label, Phase 3 Study (Brian Slomovitz, MD)
• Patient Perspective on Tisotumab Vedotin (Jennifer Clark, Patient)